Rybrevant®(Amivantamab-Vmjw)与Lazcluze®(Lazertinib)联合用药方案,作为非典型EGFR突变非小细胞肺癌的一线治疗,已证实能够带来持久的临床获益。
Rybrevant®(Amivantamab-Vmjw)与Lazcluze®(Lazertinib)联合用药方案,作为非典型EGFR突变非小细胞肺癌的一线治疗,已证实能够带来持久的临床获益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.